GEOFFREY VON MALTZAHN

Geoffrey von Maltzahn stands as a pivotal figure and General Partner at Flagship Pioneering, a unique venture creation firm known for originating and developing transformative life science companies. His distinctive approach involves not just investing in, but actively conceiving and co-founding ventures from their earliest stages. At Flagship Pioneering, von Maltzahn is a driving force behind the firm's unparalleled success in launching companies that redefine biotechnology and healthcare.

His investment focus is deeply rooted in identifying and harnessing novel biological insights to create entirely new platforms and therapeutic modalities. He specializes in building companies that tackle some of the most complex challenges in human health, agriculture, and sustainability. This includes pioneering work in areas such as gene editing, microbiome therapeutics, generative AI for drug discovery, and sustainable agriculture. Von Maltzahn's vision often leads to the formation of companies designed to create entirely new categories of medicine or industrial solutions.

Geoffrey von Maltzahn's career background is marked by a profound blend of scientific rigor and entrepreneurial drive. He earned his Ph.D. in Biological Engineering from the Massachusetts Institute of Technology (MIT) and an A.B. in Physics from Harvard University. This strong scientific foundation underpins his ability to identify truly disruptive scientific opportunities. Before joining Flagship, and throughout his tenure, he has been instrumental in the scientific conception and launch of numerous high-profile companies.

Among his many notable contributions, von Maltzahn has co-founded and played a critical role in the development of several industry-leading companies. These include Sana Biotechnology, focused on engineered cells as medicines; Tessera Therapeutics, pioneering gene writing technology; Seres Therapeutics, a leader in microbiome therapeutics; Generate Biomedicines, leveraging generative AI for protein design; and Indigo Ag, transforming agriculture through microbial and digital technologies. Other significant ventures he has helped shape include Valo Health, Cellarity, Kintai Therapeutics, Codiak Biosciences, and Rubius Therapeutics. His work consistently demonstrates a commitment to translating cutting-edge science into tangible, impactful solutions for global challenges. Through his leadership at Flagship Pioneering, Geoffrey von Maltzahn continues to shape the future of biotechnology and foster a new generation of life science innovation.